Currently, TCR-T cell therapy focuses on three types of targets: (1) tumor-associated antigens (TAAs) that are highly expressed by tumor cells but not or only weakly expressed by normal cells, such as cancer-testis antigen [14], melanoma-associated antigen-4 (MAGE-A4), and mesothelin (Fig. 2B). Here, MAGEA4 is linked to neoplasm.